TNFRSF11B and triple-A syndrome: The effect of fenofibrate on secondary parameters, including inflammatory cell (neutrophils, B-and T-lymphocytes) number, MMPs and proinflammatory cytokines within the AAA wall, periaortic fat and intramural thrombus, and circulating concentrations of AAA biomarkers, including osteoprotegerin, resistin, D-dimer and fasting lipids, will also be assessed [31, 36–38].